

108<sup>TH</sup> CONGRESS  
2<sup>D</sup> SESSION

# H. R. 5429

To require the National Institute on Drug Abuse to develop a meta-analysis of the available scientific data regarding the safety and health risks of smoking marijuana and the clinically-proven effectiveness of smoking marijuana for medicinal purposes, and to require the Food and Drug Administration to promptly disseminate the meta-analysis.

---

## IN THE HOUSE OF REPRESENTATIVES

DECEMBER 6, 2004

Mr. SOUDER (for himself, Mr. KINGSTON, Mr. SESSIONS, Mr. SMITH of New Jersey, and Mr. BONILLA) introduced the following bill; which was referred to the Committee on Energy and Commerce

---

## A BILL

To require the National Institute on Drug Abuse to develop a meta-analysis of the available scientific data regarding the safety and health risks of smoking marijuana and the clinically-proven effectiveness of smoking marijuana for medicinal purposes, and to require the Food and Drug Administration to promptly disseminate the meta-analysis.

1 *Be it enacted by the Senate and House of Representa-*  
2 *tives of the United States of America in Congress assembled,*

1 **SECTION 1. SHORT TITLE.**

2 This Act may be cited as the “Safe and Effective  
3 Drug Act”.

4 **SEC. 2. SAFETY AND EFFECTIVENESS OF SMOKING MARI-  
5 JUANA FOR MEDICINAL PURPOSES; META-  
6 ANALYSIS BY NATIONAL INSTITUTE ON DRUG  
7 ABUSE.**

8 (a) IN GENERAL.—The Director of the National In-  
9 stitutes of Health, acting through the Director of the Na-  
10 tional Institute on Drug Abuse (referred to in this Act  
11 as the “Director of the Institute”), shall develop a meta-  
12 analysis of the available scientific data regarding the safe-  
13 ty and health risks of smoking marijuana and the clini-  
14 cally-proven effectiveness of smoking marijuana for medic-  
15 inal purposes.

16 (b) COMPLETION OF META-ANALYSIS; REPORT.—  
17 Not later than 120 days after the date of the enactment  
18 of this Act, the Director of the Institute shall complete  
19 the meta-analysis under subsection (a) and submit to the  
20 Congress a report providing the meta-analysis. The Direc-  
21 tor shall transmit a copy of the report to the Commis-  
22 sioner of Food and Drugs.

23 **SEC. 3. DISSEMINATION OF META-ANALYSIS BY FOOD AND  
24 DRUG ADMINISTRATION.**

25 (a) PUBLIC ACCESS TO META-ANALYSIS THROUGH  
26 INTERNET.—Not later than 30 days after receiving from

1 the Director of the Institute the report under section 2(b),  
2 the Commissioner of Food and Drugs shall post such re-  
3 port on the Internet site of the Food and Drug Adminis-  
4 tration.

5 (b) DISSEMINATION OF META-ANALYSIS TO CERTAIN  
6 PUBLIC HEALTH AGENCIES AND OTHER APPROPRIATE  
7 ENTITIES.—Promptly after receiving from the Director of  
8 the Institute the report under section 2(b), the Commis-  
9 sioner of Food and Drugs shall disseminate the report—

10 (1) to principal public health agencies of all  
11 States, including those that authorize the smoking of  
12 marijuana for medicinal purposes; and

13 (2) to public health associations, health care  
14 professionals, and other appropriate entities that ad-  
15 vocate or recommend the smoking of marijuana by  
16 patients for medicinal purposes.

17 (c) DEFINITION.—As used in this section, the term  
18 “State” means each of the several States, the District of  
19 Columbia, the Commonwealth of Puerto Rico, the Com-  
20 monwealth of the Northern Mariana Islands, American  
21 Samoa, Guam, the Virgin Islands, and any other territory  
22 or possession of the United States.

○